Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc logo
KPTI

Karyopharm Therapeutics Inc (KPTI)

$3.4050.15%

Live
  • $

1D

1W

1M

1Y

3Y

5Y

Key Stats

$3.295
Day's Range
$3.47
$2.45
52-Week Range
$14.73
1 month return3.13%
3 month return33.98%
1 year return66.8%
5 year return72.78%

Analyst Recommendation

based on 15 analysts ratings

Buy
66%
Buy
33%
Hold
0%
Sell

Based on 15 Wall street analysts offering stock ratings for Karyopharm Therapeutics Inc(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 152.57%

Current

$3.41

Target

$8.6

Recommendation Trend

Based on 15 analyst

Current1M Ago3M Ago
Buy
10
9
9
Hold
5
6
6
Sell
0
0
0
Consensus
BUY
BUY
BUY

Company Financials

  • Annual
  • Quarterly

Highlights

Market Capitalization397.4M
Book Value- $1.73
Dividend Share0.0
Dividend Yield0.0%
Earnings Per Share (EPS)-1.42
PEG Ratio-0.15
Wall Street Target Price8.6

Valuation

Trailing PE0.0
Forward PE0.0
Price/Book (mrq)12.05
Enterprise Value412.6M
Enterprise Value/Revenue1.65
Enterprise Value/Ebitda-6.85

Technicals

Beta-0.04
50 Day MA3.69
200 Day MA4.88

Institutional Holdings

State Street Corporation

11.1%

BlackRock Inc

9.75%

Palo Alto Investors, LLC

6.93%

Vanguard Group Inc

5.93%

Rubric Capital Management LP

4.92%

Nuveen Asset Management, LLC

2.43%

Company Information

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases. Karyopharm's Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's lead compound, XPOVIO® (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade® (bortezomib) and dexamethasone for the treatment of patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. A Marketing Authorization Application for NEXPOVIO® (selinexor) for patients with heavily pretreated multiple myeloma is also currently under review by the European Medicines Agency. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.
OrganizationKaryopharm Therapeutics Inc
Employees442
CEOMr. Richard A. Paulson M.B.A.
IndustryHealth Technology

Discover more

Frequently Asked Questions

What is Karyopharm Therapeutics Inc share price today?

Can Indians buy Karyopharm Therapeutics Inc shares?

How can I buy Karyopharm Therapeutics Inc shares from India?

Can Fractional shares of Karyopharm Therapeutics Inc be purchased?

What are the documents required to start investing in Karyopharm Therapeutics Inc stocks?

What are today’s High and Low prices of Karyopharm Therapeutics Inc?

What are today’s traded volumes of Karyopharm Therapeutics Inc?

What is today’s market capitalisation of Karyopharm Therapeutics Inc?

What is the 52 Week High and Low Range of Karyopharm Therapeutics Inc?

How much percentage Karyopharm Therapeutics Inc is down from its 52 Week High?

How much percentage Karyopharm Therapeutics Inc is up from its 52 Week low?

What are the historical returns of Karyopharm Therapeutics Inc?

Who is the Chief Executive Officer (CEO) of Karyopharm Therapeutics Inc?

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*